A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
SCH66336 is a drug that has been designed to block the growth of tumor cells and encourage tumor cell death.
This is a randomized study where patients will receive study drug or no drug. Participants in this study are scheduled to have surgery to remove head and neck cancer.
Carcinoma, Squamous Cell
Cancer of Head and Neck
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||A Phase IB Study of Oral Administration of SCH 66336 Preoperatively in Patients With Head and Neck Squamous Cell Cancer Scheduled for Definitive Therapy|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00038584
|United States, Texas|
|The University of Texas M. D. Anderson Cancer Center|
|Houston, Texas, United States, 77030|